Davide Valentini1, Martin Rao2, Lalit Rane2, Sayma Rahman3, Rebecca Axelsson-Robertson1, Rainer Heuchel4, Matthias Löhr4, Daniel Hoft5, Susanna Brighenti3, Alimuddin Zumla6, Markus Maeurer7. 1. Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden; Division of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet, Stockholm, Sweden. 2. Division of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet, Stockholm, Sweden. 3. Center for Infectious Medicine (CIM), Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 4. Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden. 5. Division of Immunobiology, Departments of Internal Medicine and Molecular Microbiology, Saint Louis University Medical Centre, Saint Louis, Missouri, USA. 6. Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK. 7. Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden; Division of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet, Stockholm, Sweden. Electronic address: markus.maeurer@ki.se.
Abstract
BACKGROUND: Bacille Calmette-Guérin (BCG) is the world's most widely distributed vaccine, used against tuberculosis (TB), in cancer immunotherapy, and in autoimmune diseases due to its immunomodulatory properties. To date, the effect of BCG vaccination on antibody responses to host proteins has not been reported. High-content peptide microarrays (HCPM) offer a unique opportunity to gauge specific humoral immune responses. METHODS: The sera of BCG-vaccinated healthy adults were tested on a human HCPM platform (4953 randomly selected epitopes of human proteins) to detect specific immunoglobulin gamma (IgG) responses. Samples were obtained at 56, 112, and 252 days after vaccination. Immunohistology was performed on lymph node tissue from patients with TB lymphadenitis. Results were analysed with a combination of existing and novel statistical methods. RESULTS: IgG recognition of host peptides exhibited a peak at day 56 post BCG vaccination in all study subjects tested, which diminished over time. Primarily, IgG responses exhibited increased reactivity to ion transporters (sodium, calcium channels), cytokine receptors (interleukin 2 receptor β (IL2Rβ), fibroblast growth factor receptor 1 (FGFR1)), other cell surface receptors (inositol, somatostatin, angiopoeitin), ribonucleoprotein, and enzymes (tyrosine kinases, phospholipase) on day 56. There was decreased IgG reactivity to transforming growth factor-beta type 1 receptor (TGFβR1) and, in agreement with the peptide microarray findings, immunohistochemical analysis of TB-infected lymph node samples revealed an overexpression of TGFβR in granulomatous lesions. Moreover, the vesicular monoamine transporter (VMAT2) showed increased reactivity on days 112 and 252, but not on day 56 post-vaccination. IgG to interleukin 4 receptor (IL4R) showed increased reactivity at 112 days post-vaccination, while IgG to IL2Rβ and FGFR1 showed decreased reactivity on days 112 and 252 as compared to day 56 post BCG vaccination. CONCLUSIONS: BCG vaccination modifies the host's immune landscape after 56 days, but this imprint changes over time. This may influence the establishment of immunological memory in BCG-vaccinated individuals.
BACKGROUND: Bacille Calmette-Guérin (BCG) is the world's most widely distributed vaccine, used against tuberculosis (TB), in cancer immunotherapy, and in autoimmune diseases due to its immunomodulatory properties. To date, the effect of BCG vaccination on antibody responses to host proteins has not been reported. High-content peptide microarrays (HCPM) offer a unique opportunity to gauge specific humoral immune responses. METHODS: The sera of BCG-vaccinated healthy adults were tested on a human HCPM platform (4953 randomly selected epitopes of human proteins) to detect specific immunoglobulin gamma (IgG) responses. Samples were obtained at 56, 112, and 252 days after vaccination. Immunohistology was performed on lymph node tissue from patients with TB lymphadenitis. Results were analysed with a combination of existing and novel statistical methods. RESULTS: IgG recognition of host peptides exhibited a peak at day 56 post BCG vaccination in all study subjects tested, which diminished over time. Primarily, IgG responses exhibited increased reactivity to ion transporters (sodium, calcium channels), cytokine receptors (interleukin 2 receptor β (IL2Rβ), fibroblast growth factor receptor 1 (FGFR1)), other cell surface receptors (inositol, somatostatin, angiopoeitin), ribonucleoprotein, and enzymes (tyrosine kinases, phospholipase) on day 56. There was decreased IgG reactivity to transforming growth factor-beta type 1 receptor (TGFβR1) and, in agreement with the peptide microarray findings, immunohistochemical analysis of TB-infected lymph node samples revealed an overexpression of TGFβR in granulomatous lesions. Moreover, the vesicular monoamine transporter (VMAT2) showed increased reactivity on days 112 and 252, but not on day 56 post-vaccination. IgG to interleukin 4 receptor (IL4R) showed increased reactivity at 112 days post-vaccination, while IgG to IL2Rβ and FGFR1 showed decreased reactivity on days 112 and 252 as compared to day 56 post BCG vaccination. CONCLUSIONS: BCG vaccination modifies the host's immune landscape after 56 days, but this imprint changes over time. This may influence the establishment of immunological memory in BCG-vaccinated individuals.
Authors: Mitali Mishra; Aleena Zahra; Lokendra V Chauhan; Riddhi Thakkar; James Ng; Shreyas Joshi; Eric D Spitzer; Luis A Marcos; W Ian Lipkin; Nischay Mishra Journal: Viruses Date: 2022-04-29 Impact factor: 5.818
Authors: Nischay Mishra; Adrian Caciula; Adam Price; Riddhi Thakkar; James Ng; Lokendra V Chauhan; Komal Jain; Xiaoyu Che; Diego A Espinosa; Magelda Montoya Cruz; Angel Balmaseda; Eric H Sullivan; Jigar J Patel; Richard G Jarman; Jennifer L Rakeman; Christina T Egan; Chantal B E M Reusken; Marion P G Koopmans; Eva Harris; Rafal Tokarz; Thomas Briese; W Ian Lipkin Journal: mBio Date: 2018-03-06 Impact factor: 7.867
Authors: Nischay Mishra; Xi Huang; Shreyas Joshi; Cheng Guo; James Ng; Riddhi Thakkar; Yongjian Wu; Xin Dong; Qianlin Li; Richard S Pinapati; Eric Sullivan; Adrian Caciula; Rafal Tokarz; Thomas Briese; Jiahai Lu; W Ian Lipkin Journal: Commun Biol Date: 2021-02-12
Authors: Agnes Natukunda; Gyaviira Nkurunungi; Ludoviko Zirimenya; Jacent Nassuuna; Gloria Oduru; Rebecca Amongin; Prossy N Kabuubi; Alex Mutebe; Caroline Onen; Susan Amongi; Esther Nakazibwe; Florence Akello; Samuel Kiwanuka; Fred Kiwudhu; Moses Sewankambo; Denis Nsubuga; Robert Kizindo; Sarah G Staedke; Stephen Cose; Emily Webb; Alison M Elliott Journal: BMJ Open Date: 2021-02-16 Impact factor: 2.692